VIBOSTOLIMAB PLUS PEMBROLIZUMAB WITH/WITHOUT DOCETAXEL VS DOCETAXEL IN NSCLC AFTER PLATINUM CHEMOTHERAPY AND IMMUNOTHERAPY

被引：0
|
作者：
Peters, Solange [1 ]
Lee, Dae Ho [2 ]
Ramlau, Rodryg [3 ]
Halmos, Balazs [4 ]
Schumann, Christian [5 ]
Planchard, David [6 ]
Bhagwati, Niyati [7 ]
Chen, Diana [7 ]
Kush, Debra [7 ]
Novello, Silvia [8 ]
机构：
[1] Univ Lausanne, Ctr Hosp Univ Vaudois, Lausanne, Switzerland
[2] Asan Med Ctr, Seoul, South Korea
[3] Poznan Univ Med Sci, Poznan, Poland
[4] Montefiore Einstein Ctr Canc Care, Dept Oncol, New York, NY USA
[5] Klin Pneumol Thoraxonkol Schlaf & Beatmungsmed, Klinikverbund Allgau, Kempten, Germany
[6] Dept Med Oncol, Thorac Grp, Gustave Roussy, Villejuif, France
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Gonzaga Univ Turin, Azienda Osped Univ San Luigi, Dept Oncol, Orbassano, Italy
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.463
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
463
引用
收藏
页码：A492 / A492
页数：1
相关论文
共 50 条
  • [1] Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy
    Peters, S.
    Lee, D. H.
    Ramlau, R.
    Halmos, B.
    Schumann, C.
    Planchard, D.
    Bhagwati, N.
    Chen, Q.
    Kush, D.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1012
  • [2] Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).
    Percent, Ivor John
    Reynolds, Craig H.
    Konduri, Kartik
    Whitehurst, Matthew Thomas
    Nidhiry, Emmanuel A.
    Yanagihara, Ronald H.
    Nagasaka, Misako
    Schreeder, Marshall T.
    Uyeki, James
    Azzi, Georges
    Pachipala, Krishna Kishore
    Comer, Jason C.
    Lerner, Rachel E.
    Leal, Ticiana
    Alvarez, Delia
    Neuteboom, Saskia T. C.
    Reddinger, Natasha
    Yan, Xiaohong
    Shazer, Ronald L.
    Waterhouse, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Pembrolizumab Outperforms Docetaxel for NSCLC
    Leslie, Mitch
    CANCER DISCOVERY, 2016, 6 (03) : 223 - 223
  • [4] Docetaxel as a subsequent line after progression to platinum-based chemotherapy and immunotherapy
    Garitaonaindia, Yago
    Calvo, Virginia
    Redondo, Isabel
    Uribarren, Maria
    Ospina Serrano, Aylen Vanessa
    Collazo, Ana
    Blanco, Mariola
    Lozano, Carla
    Cutillas, Marta Martinez
    Manso, Marta
    Traseira, Cristina
    Aguado, Ramon
    Matilde Sanchez del Corral, Maria
    Provencio, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Phase 3 Trial of Sitravatinib Plus Nivolumab vs Docetaxel for Treatment of NSCLC After Platinum-Based Chemoimmunotherapy
    Nidhiry, E.
    Mekhail, T.
    Thara, E.
    Nagasaka, M.
    Chen, C.
    Gopurala, B. G.
    Campbell, N.
    Eaton, K.
    Homsi, Y.
    Yanagihara, R.
    Vaddepally, R.
    Yan, X.
    Tassell, V.
    Neuteboom, S.
    Chao, R.
    Keresztes, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S644 - S644
  • [6] Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy
    Garitaonaindia Diaz, Y.
    Calvo de Juan, V.
    Uribarren, M.
    Redondo Canovas del Castillo, I.
    Collazo Lorduy, A.
    Ospina, A. V.
    Blanco Clemente, M.
    Lozano, C.
    Manso, M.
    Martinez Cutillas, M.
    Traseira, C.
    Sanchez Gonzalez, J. C.
    Nunez Garcia, B.
    Provencio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S604 - S604
  • [7] Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum-Based Chemotherapy
    Sebastian, Martin
    Ponce, Santiago
    Nikolinakos, Petros
    Varea, Rocio
    Chao, Bo
    Zimmermann, Annamaria
    Alexandris, Ekaterine
    Lee, Pablo
    Cappuzzo, Frederico
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1079 - S1080
  • [8] Docetaxel - a therapeutic option for adjuvant chemotherapy in NSCLC
    Eberhardt, W
    ONKOLOGIE, 2000, 23 : 22 - 24
  • [9] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
    Gadgeel, Shirish
    Gandhi, Leena
    Borghaei, Hossein
    Socinski, Mark A.
    Gubens, Matthew A.
    Stevenson, James
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Papadimitrakopoulou, Vassiliki
    Bourque, Jennifer
    Bachman, Robert D.
    Ge, Joy Yang
    Im, Ellie
    Patnaik, Amita
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
  • [10] Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in Non-Squamous NSCLC: Descriptive Safety Analysis
    Govindan, R.
    Borghaei, H.
    He, S.
    Kim, J. S.
    Papadimitrakopoulou, V.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2083 - S2084
12345